<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03223909</url>
  </required_header>
  <id_info>
    <org_study_id>SOPH087-0415/IV</org_study_id>
    <nct_id>NCT03223909</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Ultra Preservative Free (087LATAMFIV)</brief_title>
  <acronym>087LATAMFIV</acronym>
  <official_title>Efficacy and Safety of the Ophthalmic Solution PRO-087 Versus Systane ® Ultra and Systane ® Ultra Preservative Free on Tear Film Dysfunction Syndrome From Mild to Moderate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratorios Sophia S.A de C.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratorios Sophia S.A de C.V.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of the Ophthalmic Solution PRO-087 versus Systane ® Ultra and Systane ®
      Ultra Preservative Free on the Tear Film Dysfunction Syndrome from Mild to Moderate Clinical
      trial To evaluate the effectiveness of preservative-free ophthalmic formulation PRO-087 (by
      Laboratorios Sophia, S.A. de C.V.) to restore the anatomical and physiological
      characteristics of the ocular surface, as well as its distribution and the characteristics of
      the mild to moderate tear film dysfunction syndrome compared to Systane ® Ultra and Ultra
      Systane ® preservative free (by Laboratorios Alcon, S.A. de C.V.).

      Controlled, randomized, double-blind, masked clinical study, comparing the safety and
      efficacy of preservative-free PR0-087 vs Systane Ultra with preservative and Systane Ultra
      preservative free, in subjects with mild to moderate tear film dysfunction syndrome, for a
      period of 90 days plus 15 days of remote surveillance, in which one of the three agents will
      be administered (PR0-087, Systane® Ultra or Systane® Ultra preservative free) with a q.i.d.
      dosage. in both eyes, with regular follow-up visits (5 overall).

      Best-corrected visual acuity Intraocular pressure Ocular surface Anterior segment examination
      Posterior segment examination Tear film break-up time Schirmer test Corneal epithelization
      Goblet cells count Adverse events Subjects with a clinical diagnosis of mild to moderate tear
      film dysfunction syndrome between 18 and 90 years old, without concomitant eye diseases nor
      requiring different treatments of any of the three interventions in this study They will be
      randomized in 3 groups where PRO-087, Systane® Ultra o Systane® Ultra preservative free will
      be administered.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design Controlled, double-blind, randomized, clinical trial comparing the safety and efficacy
      parameters between a group of subjects with a diagnose of mild to moderate tear film
      dysfunction syndrome under a regimen of ophthalmic solution lubricant drops PRO-087 versus
      subject under Systane® Ultra or Systane® Ultra preservative free, with the same diagnosis,
      with a follow-up of 90 days

      MAIN OBJECTIVE:

      To evaluate the effectiveness of preservative-free ophthalmic formulation PRO-087 (by
      Laboratorios Sophia, S.A. de C.V.) to restore the anatomical and physiological
      characteristics of the ocular surface, as well as its distribution and the characteristics of
      the mild to moderate tear film dysfunction syndrome compared to Systane ® Ultra and Ultra
      Systane ® preservative free (by Laboratorios Alcon, S.A. de C.V.).

      SPECIFIC OBJECTIVES:

      To evaluate the safety of the preservative-free ophthalmic formulation PRO-087 (by
      Laboratorios Sophia, S.A. de C.V.) on the corneal and conjunctival epithelium, intraocular
      pressure, and structures of anterior and posterior segment in patients with tear film
      dysfunction syndrome from mild to moderate.

      To determine the correlation between improvement of clinical status and perceived improvement
      of symptoms of each participant in each study group.

      To compare the qualitative and quantitative histological status of the ocular surface before
      and after the pharmacological intervention in each study group to determine the evolution
      under the intervention of PRO-087.

      To evaluate the quantitative rating of tear film production by the Schirmer Test throughout
      the study.

      To qualitatively assess the tear film production by measuring the tear film break-up time
      stained with fluorescein and cobalt filter.

      Blinding:

      The double-blind study is a procedure in which the patient and the treating doctor ignore to
      which intervention group the study patient was assigned. To achieve the blinding of both the
      drug in research and both comparator drugs, these will be labeled in the same way (masking).
      Besides the figure of an unblinded pharmacist, who is responsible for the delivery of the
      medication to the patient, will be added. Blinding codes are protected by an outsider
      appointed by the study sponsor. The codes are also available in the research center (fully
      sealed), so that they can be consulted by the investigator in case a subject presents a
      serious adverse event, prior authorization from the study sponsor; the blinding also
      continues rigorous during the data analysis and interpretation.

      patients with tear film dysfunction, classified as mild to moderate, will be included and
      randomized into 3 groups; the first being treated with PRO-087 ophthalmic solution, the
      second with Systane® Ultra ophthalmic solution, and the third with ophthalmic solution
      Systane® Ultra preservative free.

      Pharmacological Intervention

      The pharmacological intervention will be the instillation of the ophthalmic solution in the
      bottom of the conjunctival sac during the waking period, in any of the following study
      groups:

        1. Preservative free PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4
           hours for 90 days.

        2. Systane® Ultra ophthalmic solution. Dropper bottle. Multidose. 1 drop every 4 hours for
           90 days.

        3. Systane ® Ultra preservative free ophthalmic solution. Single-use vials. 1 drop every 4
           hours for 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 13, 2016</start_date>
  <completion_date type="Actual">December 16, 2018</completion_date>
  <primary_completion_date type="Actual">October 16, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Controlled, double-blind, randomized, clinical trial comparing the safety and efficacy parameters between a group of subjects with a diagnose of mild to moderate tear film dysfunction syndrome under a regimen of ophthalmic solution lubricant drops PRO-087 versus subject under Systane® Ultra or Systane® Ultra preservative free, with the same diagnosis, with a follow-up of 90 days.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The double-blind study is a procedure in which the patient and the treating doctor ignore to which intervention group the study patient was assigned. To achieve the blinding of both the drug in research and both comparator drugs, these will be labeled in the same way (masking). Besides the figure of an unblinded pharmacist, who is responsible for the delivery of the medication to the patient, will be added. Blinding codes are protected by an outsider appointed by the study sponsor. The codes are also available in the research center (fully sealed), so that they can be consulted by the investigator in case a subject presents a serious adverse event, prior authorization from the study sponsor; the blinding also continues rigorous during the data analysis and interpretation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>Change from Baseline visual acuity at 90 days</time_frame>
    <description>Best-corrected visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Corneal Epithelization Defects With Rose of Bengal</measure>
    <time_frame>Final Visit (day 90)</time_frame>
    <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tear Film Break-up Time (TBUT)</measure>
    <time_frame>Base line and Final Visit (day 90)</time_frame>
    <description>Tear breakup time (TBUT) is a clinical test used to assess for evaporative dry eye disease. To measure TBUT, fluorescein is instilled into the patient's tear film and the patient is asked not to blink while the tear film is observed under a broad beam of cobalt blue illumination. The TBUT is recorded as the number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film, as seen in this progression of these slit lamps photos over time. A TBUT under 10 seconds is considered abnormal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer Test</measure>
    <time_frame>Base line and Final Visit (day 90)</time_frame>
    <description>Schirmer's test determines whether the eye produces enough tears to keep it moist. This test is used when a person experiences very dry eyes or excessive watering of the eyes. It poses no risk to the subject. A negative (more than 10 mm of moisture on the filter paper in 5 minutes) test result is normal. Both eyes normally secrete the same amount of tears.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>90 days</time_frame>
    <description>Presence of adverse events modifying some of the abovementioned criteria or others, evaluated as serious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index (OSDI)</measure>
    <time_frame>Change from Baseline OSDI at 90 days</time_frame>
    <description>The OSDI, which was created to order to quickly assess the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to &quot;none of the time&quot; and 4 corresponding to &quot;all of the time.&quot; A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Goblet Cells Population</measure>
    <time_frame>Change from Baseline Goblet cells population at 90 days</time_frame>
    <description>Increase of 20% from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal Epithelization Defects With Fluorescein</measure>
    <time_frame>Final Visit (day 90)</time_frame>
    <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">326</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>PRO-087 PF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane Ultra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Systane Ultra PF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-087</intervention_name>
    <description>0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
    <arm_group_label>PRO-087 PF</arm_group_label>
    <other_name>Chondroitin sulfate</other_name>
    <other_name>sodium hyaluronate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Ultra</intervention_name>
    <description>Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
    <arm_group_label>Systane Ultra</arm_group_label>
    <other_name>polyethylene glycol 400, propylene glycol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systane Ultra Preservative Free</intervention_name>
    <description>Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
    <arm_group_label>Systane Ultra PF</arm_group_label>
    <other_name>Polyethylene Glycol 400 0.4%, Propylene Glycol 0.3%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 to &lt; 90 years old

          -  Both sexes

          -  Mild to moderate tear film dysfunction clinical diagnose

          -  Mild to moderate clinical stage of the disease

               -  TBUT &gt; 5 sec. and &lt; 10 sec.

               -  Schirmer: &gt; 4 mm and &lt; 14 mm

               -  OSDI &lt; 30 points

               -  Corneal staining &lt; grade III on the Oxford scale

          -  Availability to go to each revision when indicated.

        Exclusion Criteria:

        General Criteria

          1. Subjects with topical and/or systemic medication or mechanical devices that interfere
             determinedly on the results of the study (such as topical immunomodulators, punctal
             plugs, corticosteroids, preservative artificial tears, contact lenses).

          2. Subjects (females) with active sexual life that do not use a contraceptive method.

          3. Female subjects who are pregnant or lactating

          4. Female subjects with a positive urine pregnancy test

          5. Positive drug addictions* (verbal interrogatory)

          6. Subjects who have participated on any other research clinical trials on the last 40
             days

          7. Subjects legal or mentally disabled to give an informed consent for participating on
             this study

          8. Subjects who can't comply with the appointments or with every protocol requirement.

        Criteria related with ophthalmic ailments

          1. Serious tear film dysfunction syndrome TBUT &lt; 5 s Schirmer: &lt; 4 mm OSDI &gt; 30 pints
             Corneal staining &gt; grade III on the Oxford scale

          2. Non perforated corneal ulcer

          3. Perforated corneal ulcer

          4. Autoimmune corneal ulcer

          5. Ocular surface scarring diseases

          6. Ocular surface or annexes metaplastic lesions

          7. Fibro vascular proliferation lesions on the conjunctival and/or corneal surface (i.e.:
             pterygium)

          8. Concomitant chronic inflammatory diseases on any ocular structure

          9. Acute or infectious inflammatory disease

         10. Corneal disease potentially requiring a treatment during the following 3 months

         11. Use of topical or systemic drug products classified as forbidden

         12. Ocular surgical procedures 3 months before the protocol inclusion

         13. Treatments or procedures indicated on the tear film dysfunction treatment, as punctal
             silicone plugs.

         14. Posterior segment diseases requiring a treatment or threatening the visual prognosis

         15. Retinal diseases potentially requiring treatment during the following 3 months

         16. History of penetrating keratoplasty.

         17. Soft or hard contact lenses use during the last month from inclusion day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leopoldo Baiza, MD</last_name>
    <role>Study Director</role>
    <affiliation>Laboratorios Sophia S.A de C.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fernando Rodriguez Sixtos Higuera</name>
      <address>
        <city>Irapuato</city>
        <state>Guanajuato</state>
        <zip>36670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>June 22, 2017</study_first_submitted>
  <study_first_submitted_qc>July 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2017</study_first_posted>
  <results_first_submitted>June 5, 2019</results_first_submitted>
  <results_first_submitted_qc>October 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 31, 2019</results_first_posted>
  <last_update_submitted>October 30, 2019</last_update_submitted>
  <last_update_submitted_qc>October 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>Chondroitin sulfate</keyword>
  <keyword>Ocular lubricants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>For security and laws implemented by the regulatory entity can not share personal data of research subjects.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/09/NCT03223909/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PRO-087 PF</title>
          <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
        </group>
        <group group_id="P2">
          <title>Systane Ultra</title>
          <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
        </group>
        <group group_id="P3">
          <title>Systane Ultra PF</title>
          <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="97"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PRO-087 PF</title>
          <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
        </group>
        <group group_id="B2">
          <title>Systane Ultra</title>
          <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
        </group>
        <group group_id="B3">
          <title>Systane Ultra PF</title>
          <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="72"/>
            <count group_id="B2" value="64"/>
            <count group_id="B3" value="81"/>
            <count group_id="B4" value="217"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.5" spread="15.3"/>
                    <measurement group_id="B2" value="55.0" spread="17.6"/>
                    <measurement group_id="B3" value="51.9" spread="16.2"/>
                    <measurement group_id="B4" value="54.2" spread="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="63"/>
                    <measurement group_id="B4" value="161"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="217"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Acuity</title>
        <description>Best-corrected visual acuity</description>
        <time_frame>Change from Baseline visual acuity at 90 days</time_frame>
        <population>the statistical analysis was carried out by intention to treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Best-corrected visual acuity</description>
          <population>the statistical analysis was carried out by intention to treat (ITT)</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.187" spread="0.25"/>
                    <measurement group_id="O2" value="0.215" spread="0.26"/>
                    <measurement group_id="O3" value="0.219" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.172" spread="0.24"/>
                    <measurement group_id="O2" value="0.187" spread="0.24"/>
                    <measurement group_id="O3" value="0.176" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%
Statistical analysis of groups in the baseline visit versus final visit</non_inferiority_desc>
            <p_value>0.080</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%
Statistical analysis between groups in the final visit</non_inferiority_desc>
            <p_value>0.848</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Epithelization Defects With Rose of Bengal</title>
        <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
        <time_frame>Final Visit (day 90)</time_frame>
        <population>the statistical analysis was carried out by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelization Defects With Rose of Bengal</title>
          <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
          <population>the statistical analysis was carried out by intention to treat</population>
          <units>percentage of defects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.6"/>
                    <measurement group_id="O2" value="73.4"/>
                    <measurement group_id="O3" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%</non_inferiority_desc>
            <p_value>0.468</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tear Film Break-up Time (TBUT)</title>
        <description>Tear breakup time (TBUT) is a clinical test used to assess for evaporative dry eye disease. To measure TBUT, fluorescein is instilled into the patient's tear film and the patient is asked not to blink while the tear film is observed under a broad beam of cobalt blue illumination. The TBUT is recorded as the number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film, as seen in this progression of these slit lamps photos over time. A TBUT under 10 seconds is considered abnormal</description>
        <time_frame>Base line and Final Visit (day 90)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Film Break-up Time (TBUT)</title>
          <description>Tear breakup time (TBUT) is a clinical test used to assess for evaporative dry eye disease. To measure TBUT, fluorescein is instilled into the patient's tear film and the patient is asked not to blink while the tear film is observed under a broad beam of cobalt blue illumination. The TBUT is recorded as the number of seconds that elapse between the last blink and the appearance of the first dry spot in the tear film, as seen in this progression of these slit lamps photos over time. A TBUT under 10 seconds is considered abnormal</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.08" spread="1.01"/>
                    <measurement group_id="O2" value="7.10" spread="1.01"/>
                    <measurement group_id="O3" value="7.10" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.28" spread="2.3"/>
                    <measurement group_id="O2" value="8.46" spread="2.6"/>
                    <measurement group_id="O3" value="8.52" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>population analysis was per protocol</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>population analysis was per protocol</non_inferiority_desc>
            <p_value>0.650</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Schirmer Test</title>
        <description>Schirmer's test determines whether the eye produces enough tears to keep it moist. This test is used when a person experiences very dry eyes or excessive watering of the eyes. It poses no risk to the subject. A negative (more than 10 mm of moisture on the filter paper in 5 minutes) test result is normal. Both eyes normally secrete the same amount of tears.</description>
        <time_frame>Base line and Final Visit (day 90)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Schirmer Test</title>
          <description>Schirmer's test determines whether the eye produces enough tears to keep it moist. This test is used when a person experiences very dry eyes or excessive watering of the eyes. It poses no risk to the subject. A negative (more than 10 mm of moisture on the filter paper in 5 minutes) test result is normal. Both eyes normally secrete the same amount of tears.</description>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>basal visit (day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.48" spread="2.5"/>
                    <measurement group_id="O2" value="9.05" spread="2.7"/>
                    <measurement group_id="O3" value="9.25" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.19" spread="4.2"/>
                    <measurement group_id="O2" value="12.21" spread="4.5"/>
                    <measurement group_id="O3" value="12.16" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>It was considered as not inferior when the treatments did not present differences greater than 20%
Statistical analysis of Humylub® Ofteno (PRO-087) versus Systane® Ultra PF at the final visit.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>It was considered as not inferior when the treatments did not present differences greater than 20% Statistical analysis of Humylub® Ofteno (PRO-087) versus Systane® Ultra PF at the final visit.</non_inferiority_desc>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Presence of adverse events modifying some of the abovementioned criteria or others, evaluated as serious.</description>
        <time_frame>90 days</time_frame>
        <population>Statistical analysis was performed by protocol (PP)</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Presence of adverse events modifying some of the abovementioned criteria or others, evaluated as serious.</description>
          <population>Statistical analysis was performed by protocol (PP)</population>
          <units>percentage of adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="109"/>
                <count group_id="O3" value="97"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="21.1"/>
                    <measurement group_id="O3" value="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>the statistical analysis was carried out by intention to treat
It was considered as not inferior when the treatments did not present differences greater than 20%</non_inferiority_desc>
            <p_value>0.930</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Surface Disease Index (OSDI)</title>
        <description>The OSDI, which was created to order to quickly assess the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to &quot;none of the time&quot; and 4 corresponding to &quot;all of the time.&quot; A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.</description>
        <time_frame>Change from Baseline OSDI at 90 days</time_frame>
        <population>The statistical analysis was carried out by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Disease Index (OSDI)</title>
          <description>The OSDI, which was created to order to quickly assess the symptoms of ocular irritation in dry eye disease and how they affect functioning related to vision. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers. Patients rate their responses on a 0 to 4 scale with 0 corresponding to &quot;none of the time&quot; and 4 corresponding to &quot;all of the time.&quot; A final score is calculated which ranges from 0 to 100 with scores 0 to 12 representing normal, 13 to 22 representing mild dry eye disease, 23 to 32 representing moderate dry eye disease, and greater than 33 representing severe dry eye disease.</description>
          <population>The statistical analysis was carried out by intention to treat</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.59" spread="7.3"/>
                    <measurement group_id="O2" value="15.74" spread="7.0"/>
                    <measurement group_id="O3" value="16.31" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.99" spread="8.2"/>
                    <measurement group_id="O2" value="7.47" spread="8.8"/>
                    <measurement group_id="O3" value="6.32" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%</non_inferiority_desc>
            <p_value>0.548</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Goblet Cells Population</title>
        <description>Increase of 20% from baseline</description>
        <time_frame>Change from Baseline Goblet cells population at 90 days</time_frame>
        <population>the statistical analysis was carried out by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Goblet Cells Population</title>
          <description>Increase of 20% from baseline</description>
          <population>the statistical analysis was carried out by intention to treat</population>
          <units>cells/mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Base Line</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="341.2" spread="136.9"/>
                    <measurement group_id="O2" value="338.5" spread="150.6"/>
                    <measurement group_id="O3" value="327.4" spread="146.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="447.3" spread="173.4"/>
                    <measurement group_id="O2" value="413.5" spread="157.7"/>
                    <measurement group_id="O3" value="442.6" spread="147.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%</non_inferiority_desc>
            <p_value>0.170</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Corneal Epithelization Defects With Fluorescein</title>
        <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
        <time_frame>Final Visit (day 90)</time_frame>
        <population>the statistical analysis was carried out by intention to treat</population>
        <group_list>
          <group group_id="O1">
            <title>PRO-087 PF</title>
            <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
          </group>
          <group group_id="O2">
            <title>Systane Ultra</title>
            <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
          </group>
          <group group_id="O3">
            <title>Systane Ultra PF</title>
            <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
          </group>
        </group_list>
        <measure>
          <title>Corneal Epithelization Defects With Fluorescein</title>
          <description>Percentage of the damaged epithelium of the ocular surface, reduction of staining according to the oxford scale.</description>
          <population>the statistical analysis was carried out by intention to treat</population>
          <units>percentage of defects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="64"/>
                <count group_id="O3" value="81"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal (0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8"/>
                    <measurement group_id="O2" value="53.1"/>
                    <measurement group_id="O3" value="53.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Very mild (1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8"/>
                    <measurement group_id="O2" value="36.7"/>
                    <measurement group_id="O3" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild (2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate (3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe (4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>it was considered as not inferior when the treatments did not present differences greater than 20%</non_inferiority_desc>
            <p_value>0.085</p_value>
            <method>Chi-squared, Corrected</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored and recorded throughout the study, an average of 2 years, since october 2016 to october 2018.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PRO-087 PF</title>
          <description>Preservative free (PF) PRO-087 ophthalmic solution. Dropper bottle. Multidose 1 drop every 4 hours for 90 days.
PRO-087: 0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate</description>
        </group>
        <group group_id="E2">
          <title>Systane Ultra</title>
          <description>Systane Ultra ophthalmic solution, Dropper bottle, Multidose.
1 drop every 4 hours for 90 days.
Systane Ultra: Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.</description>
        </group>
        <group group_id="E3">
          <title>Systane Ultra PF</title>
          <description>Systane Ultra, preservative free ophthalmic solution, single-use vials.
1 drop every 4 hours for 90 days.
Systane Ultra Preservative Free: Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="120"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="109"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ringing in ears</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>bacterial conjunctivitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Defect of the corneal epithelium</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Allergic conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Eyelid spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Feeling of burning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Red eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Prurito en el ojo</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="109"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in the eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>enteroviric gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Episodes of aggravated nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Bacterial gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Nuisance in the area of application</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Light fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Flexo-extension injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bacterial urinary infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Faringoamigdalitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>flu</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contact dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Cellulitis of the finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="120"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="97"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>IPs may not share, disclose or partially or completely publish the information of this research in order to request and receive written approval from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ricardo Alonso Llamas Velázquez (clinical safety pharmacologist)</name_or_title>
      <organization>Laboratorios Sophia</organization>
      <phone>+52 (33) 3001 4200 ext 1259</phone>
      <email>ricardo.llamas@sophia.com.mx</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

